FDA Advised to Update Labels on GLP-1 Weight-Loss Drugs
In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.
Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.
GLP-1 weight-loss drugs might help protect kidneys
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to date on the effects of the drugs on the kidneys,
What Are Compounded GLP-1 Medications for Weight Loss?
GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard of them under brand names like Ozempi​​c® and Wegovy® (semaglutide) or Monjouro and Zepbound (tirzepatide).
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
HealthDay on MSN22h
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...
Medscape6d
Side Effects of GLP-1 Drugs: What Doctors Should Know
Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...
BioSpace1d
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
News Medical on MSN9d
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder
Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...
Becker's Hospital Review1d
GLP-1's $411B conundrum
Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.
More than half of US adults could benefit from GLP-1 medications, researchers find
In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth ...
News Medical on MSN14h
GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events
Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.
MedPage Today2d
Are GLP-1 Drugs Putting an End to Bariatric Surgery?
We go into depth, covering what bariatric surgery is, who needs it, why insurance makes it so hard to get it, and, most ...